← Back to Search

Other

LY3502970 (Part A) for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 92 days postdose
Awards & highlights

Study Summary

This trial tests how well a drug, LY3502970, is absorbed and eliminated in overweight and obese patients and if it's safe and tolerated. It also looks at how food affects it. 135 days total.

Eligible Conditions
  • Healthy Subjects
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 92 days postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 92 days postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: Maximum Observed Concentration (Cmax) of LY3502970
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970
Secondary outcome measures
PK: AUC[0-24] of LY3502970 in fed state
PK: Cmax of LY3502970 in fed state
PK: Tmax of LY3502970 in fed state

Side effects data

From 2022 Phase 2 trial • 383 Patients • NCT05048719
37%
Nausea
33%
Vomiting
26%
Diarrhoea
22%
Constipation
19%
Eructation
11%
Weight decreased
11%
Dyspepsia
11%
Flatulence
7%
Asthenia
7%
Urticaria
7%
Abdominal pain upper
7%
Abdominal distension
7%
Retching
7%
Decreased appetite
7%
Haemoglobin decreased
4%
Ischaemic stroke
4%
Fatigue
4%
Lipase increased
4%
Arthralgia
4%
Hypertension
4%
Palpitations
100%
80%
60%
40%
20%
0%
Study treatment Arm
36 mg LY3502970 - 1
45 mg LY3502970 - 1
12 mg LY3502970
24 mg LY3502970
36 mg LY3502970 - 2
Placebo
3 mg LY3502970
45 mg LY3502970 - 2
1.5 mg Dulaglutide

Trial Design

2Treatment groups
Experimental Treatment
Group I: LY3502970 (Part B)Experimental Treatment1 Intervention
The multiple doses of LY3502970 administered orally in tablet formulation.
Group II: LY3502970 (Part A)Experimental Treatment1 Intervention
The multiple doses of LY3502970 administered orally either in tablet or capsule formulations.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3502970
2021
Completed Phase 2
~1240

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,624 Previous Clinical Trials
3,216,869 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,349 Previous Clinical Trials
415,628 Total Patients Enrolled

Media Library

LY3502970 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05841238 — Phase 1
Healthy Subjects Research Study Groups: LY3502970 (Part A), LY3502970 (Part B)
Healthy Subjects Clinical Trial 2023: LY3502970 Highlights & Side Effects. Trial Name: NCT05841238 — Phase 1
LY3502970 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05841238 — Phase 1
Healthy Subjects Patient Testimony for trial: Trial Name: NCT05841238 — Phase 1
~25 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top